Author:
Morishima Toshitaka,Ikai Hiroshi,Imanaka Yuichi
Subject
Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)
Reference30 articles.
1. The Global Initiative for Asthma. GINA Report, Global Burden of Asthma. National Heart, Lung, and Blood Institute; National Institutes of Health, USA; and World Health Organization, 2004, Gaithersburg, MD. Available from: http://www.ginasthma.org/reports-global-burden-of-asthma.html [Accessed December 18, 2012].
2. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma;Bousquet;J Allergy Clin Immunol,2010
3. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE;Humbert;Allergy,2005
4. Predicting and evaluating response to omalizumab in patients with severe allergic asthma;Bousquet;Respir Med,2007
5. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update;Holgate;Respir Med,2009
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献